The Medical Letter on Drugs and Therapeutics
Drugs and Devices for Weight Management
May 30, 2022 (Issue: 1651)Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has...more
- KH Lewis et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring) 2019; 27:591.
- DB Allison et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20:330.
- KM Gadde et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341.
- WT Garvey et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297.
- Q Shi et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomized controlled trials. Lancet 2022; 399:259.
- AS Kelly et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid 2022 April 30 (epub).
- KM Gadde et al. Obesity: pathophysiology and management. J Am Coll Cardiol 2018; 71:69.
- P Hollander et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022.
- Contrave – a combination of bupropion and naltrexone for weight loss. Med Lett Drugs Ther 2014; 56:112.
- A Siebenhofer et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2021; 1:CD007654.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.
- Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015; 57:89.
- MJ Davies et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015; 314:687.
- X Pi-Sunyer et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373:11.
- TA Wadden et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 2013; 37:1443.
- CW le Roux et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389:1399.
- JR Lundgren et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 2021; 384:1719.
- Semaglutide (Wegovy) for weight loss. Med Lett Drugs Ther 2021; 63:106.
- JPH Wilding et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.
- TA Wadden et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021; 325:1403.
- D Rubino et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021; 325:1414.
- M Davies et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397:971.
- DM Rubino et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022; 327:138.
- L He et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2022 Mar 28 (epub).
- JP Frias et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385:503.
- AspireAssist – a new device for weight loss. Med Lett Drugs Ther 2016; 58:109.
- T Muniraj et al. AGA clinical practice guidelines on intragastric balloons in the management of obesity. Gastroenterology 2021; 160:1799.
- AA Saber et al. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Surg 2017; 27:277.
- ReShape and Orbera – two gastric balloon devices for weight loss. Med Lett Drugs Ther 2015; 57:122.
- BK Abu Dayyeh et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82:425.
- DL Chan et al. Outcomes with intra-gastric balloon therapy in BMI <35 non-morbid obesity: 10-year follow-up study of an RCT. Obes Surg 2021; 31:781.
- Obalon Balloon System – another gastric balloon for weight loss. Med Lett Drugs Ther 2017; 59:102.
- S Sullivan et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis 2018; 14:1876.
- FDA. Update: potential risks with liquid-filled intragastric balloons – letter to health care providers. April 27, 2020. https://bit.ly/3uVOZFv. Accessed May 12, 2022.
- Plenity for weight management. Med Lett Drugs Ther 2021; 63:77.
- FL Greenway et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity (Silver Spring) 2019; 27:205.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.